Search

Your search keyword '"Inmaculada de la Torre"' showing total 94 results

Search Constraints

Start Over You searched for: Author "Inmaculada de la Torre" Remove constraint Author: "Inmaculada de la Torre"
94 results on '"Inmaculada de la Torre"'

Search Results

1. Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study

2. Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis

3. The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis

4. Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review

5. Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN

6. Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

7. Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions

8. Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib

9. A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate

10. Las cerámicas griegas áticas de figuras rojas de Zacatín (Granada, España)

11. Cuantificación en cerámica, ¿ejercicio especulativo o ejercicio hipotético? Las cerámicas ibéricas y púnicas en la Iliberri del siglo IV a.C. procedentes del depósito de la calle Zacatín (Granada)

12. Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study.

13. Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus

14. A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2

15. Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study

16. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52

17. A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate

18. Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial

19. Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis

20. Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52

21. Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis

22. Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy

23. Correction to: Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52

24. Neutralizing monoclonal antibodies for treatment of COVID-19

25. Baricitinib and the Risk of Incident Interstitial Lung Disease: A Descriptive Clinical Case Report from Clinical Trials

26. Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib

27. P204 Effect of baricitinib on functional impairment in RA patients with moderate disease activity and an inadequate response to conventional DMARDs

28. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study

29. Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis

30. Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritis—going beyond treat to target

31. Clinical and Genetic Diagnosis of Nonischemic Sudden Cardiac Death

32. Diagnóstico clínico y genético de la muerte súbita cardiaca de origen no isquémico

33. Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related)

34. Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis

35. Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM

36. Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib

37. Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

38. OP0313 COST-EFFECTIVENESS OF A JAK1/JAK2-INHIBITOR VS. A BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG IN A TREAT-TO-TARGET STRATEGY FOR RHEUMATOID ARTHRITIS

39. 074 Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis

40. Treat-to-target and treat-to-budget in rheumatoid arthritis: Measuring the value of Individual therapeutic interventions

41. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

42. Penetrancia familiar en la parada cardíaca en ausencia de cardiopatía aparente: observaciones del estudio FIVI-Gen

43. Cuantificación en cerámica, ¿ejercicio especulativo o ejercicio hipotético? Las cerámicas ibéricas y púnicas en la Iliberri del siglo IV a.C. procedentes del depósito de la calle Zacatín (Granada)

44. The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib

45. Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

46. Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis

47. FRI0607 Long-term and optimization of infliximab in refractory uveitis associated to behÇet disease. multicentre study of 100 patients

48. THU0326 Short and long-term follow-up with adalimumad in refractory uveitis associated to behÇet's disease. multicenter study of 74 patients

49. Rheumatoid arthritis oral abstractsO01. Efficacy and Safety of Baricitinib Versus Placebo and Adalimumab in Patients with Moderately to Severely Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Summary Results from the 52-Week Phase 3 RA-Beam Study

50. 216. BARICITINIB, METHOTREXATE, OR BARICITINIB PLUS METHOTREXATE IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAD RECEIVED LIMITED OR NO TREATMENT WITH DMARDS: EFFICACY AND SAFETY RESULTS FROM THE 52-WEEK PHASE 3 RA-BEGIN STUDY

Catalog

Books, media, physical & digital resources